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Southwest (SW) Taiwan has been the site for
health studies for more than 45 years, initially
because of the discovery of a unique periph-
eral vascular disease, blackfoot disease (BFD),
that led to gangrenous amputation of the
extremities and later because of the associa-
tions between high arsenic levels in local arte-
sian well water and a variety of diseases,
including cancers. A review of the history of
these studies is useful as they have been used
to estimate the carcinogenic risk from the
ingestion of inorganic arsenic.
Epidemiologic studies on BFD were con-
ducted by the Institute of Public Health of the
National Taiwan University. All cases of BFD
were found to have used the local artesian wells
(Chen and Wu 1962), which were found to
have high levels of arsenic (0.35–1.10 ppm)
and algae (Chen et al. 1962). A high level of
arsenic was suspected to be the most likely
causal factor, although organic toxins from the
algae were also considered (Chen et al. 1962),
as later were ﬂuorescent or humic substances
(Lu 1990). BFD was particularly prevalent in
the townships of Pei-men, Hsieh-chia, and
Pu-tai (Chen and Wu 1962).
In 1965 a dermatologic survey was con-
ducted in 37 villages in the BFD-endemic
area, which found close associations between
BFD, signs of chronic arsenicism (hyper-
pigmentation and keratosis), and skin cancer
(Tseng et al. 1968). This study showed a
dose–response relationship for both BFD
and skin cancer with respect to arsenic level,
when well water arsenic level was stratiﬁed as
< 0.30 ppm, 0.30–0.59 ppm, and ≥ 0.60
ppm (mg/L).
A death certiﬁcate study (1968–1982) was
conducted on 84 villages in the BFD-endemic
area that found a dose–response relationship
between standardized mortality ratios (SMRs)
of certain cancers and BFD prevalence rates of
the villages and townships (Chen et al. 1985).
The highest cancer rates were for the town-
ships of Pei-men, Hsieh-chia, and Pu-tai, and
the lowest for the township of I-chu. Cancer
SMRs were greatest in the villages where only
artesian wells were used as the drinking water.
This study was revamped in order to study
arsenic levels as a risk factor. Because well
water arsenic levels from the 1964–1966 sur-
vey (Kuo 1968) were known only for 27 of the
84 villages, the study was extended to include
an additional 15 villages from the neighboring
townships of Yen-shui and Hsia-in. The
expanded study (Wu et al. 1989) also stratiﬁed
villages by their median well water arsenic level
as < 0.30, 0.30–0.59, and ≥ 0.60 ppm. The
data of Wu et al. (1989) with the addition of
an exposure stratum of median well water
arsenic level < 0.1 ppm were used to calculate
cancer potency indices (Chen et al. 1992). The
potency indices for excess lifetime risk due to
an intake of 10 µg/kg/day of arsenic were
about 1.5 × 10–2 for male and female bladder
cancers and lung cancers.
Morales et al. (2000) used the Wu et al.
(1989) raw study data to model arsenic-
attributed cancer risk, using village-specific
census and mortality data and village-speciﬁc
median well water arsenic levels rather than
using the three-level arsenic strata methodol-
ogy employed by Tseng et al. (1968) and Wu
et al. (1989). Risks were calculated using a
variety of models, either with SW Taiwan or
all of Taiwan as the comparison population,
and with no comparison population. The
exposure–response curves showed a wide
range of slopes at low-dose levels, depending
upon choice of comparison population,
model, and model parameters. Morales et al.
(2000) performed a stratified SMR analysis
using narrower strata than those of the
Wu et al. (1989) study.
The U.S. Environmental Protection
Agency (U.S. EPA 2001, 2005) and the
National Research Council (NRC 1999a,
2001) have each used particular ﬁts from the
Morales et al. (2000) data set analysis as their
basis for estimating the carcinogenic risk from
the ingestion of inorganic arsenic. These esti-
mates, like those of Morales et al. (2000), used
the median village arsenic level as the sole
explanatory variable for estimating the risk.
The estimates also assumed a linear no-thresh-
old model for extrapolation to low doses.
Previous analysis of the cancer mortality in
the BFD-endemic area had shown township
to be a discriminating factor for carcinogenic
risk. Chen et al. (1985) stated that “the higher
the BFD prevalence rate of a township, the
greater the SMRs for cancers of bladder, kid-
ney, skin, and lung of the township.” This
article adds township as an explanatory vari-
able in the quantitative analysis of the study
by Wu et al. (1989).
We have expanded a data set of Wu et al.
(1989) received from A. Schulman (U.S. EPA)
and L. Ryan (Harvard University) by adding
township and well water arsenic level informa-
tion published by the NRC (1999b) and have
examined the dose–response relationship for
both the low-dose villages and high-dose vil-
lages with respect to possible explanatory vari-
ables, including township, apart from arsenic
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Quantitative analysis for the risk of human cancer from the ingestion of inorganic arsenic has been
based on the reported cancer mortality experience in the blackfoot disease (BFD)–endemic area of
southwest Taiwan. Linear regression analysis shows that arsenic as the sole etiologic factor accounts
for only 21% of the variance in the village standardized mortality ratios for bladder and lung can-
cer. A previous study had reported the inﬂuence of confounders (township, BFD prevalence, and
artesian well dependency) qualitatively, but they have not been introduced into a quantitative
assessment. In this six-township study, only three townships (2, 4, and 6) showed a signiﬁcant posi-
tive dose–response relationship with arsenic exposure. The other three townships (0, 3, and 5)
demonstrated signiﬁcant bladder and lung cancer risks that were independent of arsenic exposure.
The data for bladder and lung cancer mortality for townships 2, 4, and 6 ﬁt an inverse linear regres-
sion model (p < 0.001) with an estimated threshold at 151 µg/L (95% conﬁdence interval, 42 to
229 µg/L). Such a model is consistent with epidemiologic and toxicologic literature for bladder can-
cer. Exploration of the southwest Taiwan cancer mortality data set has clariﬁed the dose–response
relationship with arsenic exposure by separating out township as a confounding factor. Key words:
arsenic, blackfoot disease, bladder cancer, cancer risk, confounder, dose–response relationship,
southwest Taiwan, threshold model. Environ Health Perspect 114:1077–1082 (2006).
doi:10.1289/ehp.8704 available via http://dx.doi.org/ [Online 13 January 2006]level (Table 1). Data can be obtained at StatLib
website hosted by Carnegie Mellon University
(Carnegie Mellon University 2006); click on
"Get Data," then search the term “arsenic.”
Materials and Methods
Data underlying the study by Wu et al.
(1989) are analyzed in this report. That study
examined the 1973–1986 cancer mortality for
the 42 study villages, based on death certifi-
cates that were coded to the International
Classification of Diseases: Manual of the
International Statistical Classification of
Diseases, Injuries, and Causes of Death, 8th
Revision (World Health Organization 1965),
person-year distributions based on Taiwan
household registration office data and in the
data set of Morales et al. (2000) for study pop-
ulation and bladder and lung cancer deaths,
and median village well water arsenic level as
reported by the NRC (1999b). The outcome
variables in the Morales et al. data set were
limited to bladder and lung cancer mortality.
We performed linear regression analyses
of the village data using Excel (Microsoft
Corp., Redmond, WA) least-squares analysis
with the village SMRs as dependent observa-
tions and with median village well water
arsenic level as a continuous predictor.
Approximate 95% conﬁdence intervals (CIs)
on x-intercepts from inverse linear regression
were calculated. SMR = 100 was used as the
reference value because it represents the SMR
value at which the risk is not increased above
that of the reference population. Stratified
analyses have been based on township (indi-
vidual or grouped), number of reported wells
per village (one vs. multiple), artesian well
dependency, and exposure strata (low vs.
higher: < 0.13 ppm vs. > 0.25 ppm). The
townships were identified by number by the
NRC (1999b). The number of wells in each
village was also identified by the NRC
(1999b). Twenty villages had only one
reported well, 10 had two wells, 7 had three
to five wells, and 5 had six or more wells.
Questions of measurement error or exposure
misassignment have been raised, either
because of the wide range of measurements
that might be behind a median (Morales et al.
1999) or because the measured well may not
Lamm et al.
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Table 1. Internal cancer data from arsenic-exposure studies conducted in Taiwan region endemic to BFD (corrected).
No. of  Person-years Bladder Lung Liver
Village wells Arsenic concentration (ppm) Median MF M F M F M F
1 3-H 1 0.010 0.010 4,159 4,043 1 6 3 5 3 1
2 2-I 1 0.011 0.011 3,529 3,194 0 0 0 1 0 0
3 0-G 5 0.010, 0.010, 0.030, 0.259, 0.770 0.030 5,388 4,861 3 2 4 5 3 3
4 3-5 1 0.032 0.032 7,851 7,033 3 3 6 2 5 2
5 3-N 1 0.032 0.032 2,689 2,392 4 3 3 1 1 1
6 4-7 1 0.042 0.042 10,629 10,227 0 0 0 0 4 0
7 6-A 1 0.045 0.045 7,716 6,820 0 0 0 0 1 1
8 0-J 2 0.020, 0.080 0.050 6,501 5,888 1 0 0 0 2 2
9 3-L 2 0.053, 0.058 0.056 6,238 5,094 3 4 5 7 3 0
10 4-D 1 0.060 0.060 10,107 9,227 1 2 1 1 1 1
11 3-P 1 0.065 0.065 6,574 5,927 0 0 2 5 3 0
12 6-C 1 0.073 0.073 12,767 11,937 0 1 2 0 2 0
13 4-8 1 0.080 0.080 11,307 10,332 1 0 2 2 3 1
14 O-O 1 0.100 0.100 6,895 6,392 0 0 3 1 2 2
15 O-E 5 0.010, 0.085, 0.110, 0.288, 0.686 0.110 5,753 5,310 6 3 4 5 3 1
16 O-I 7 0.020, 0.050, 0.110, 0.110, 0.190, 0.580, 0.590 0.110 4,249 3,833 0 2 3 2 1 3
17 4-N 2 0.073, 0.172 0.123 4,709 4,291 0 0 1 2 3 1
18 4-J 1 0.126 0.126 6,508 6,026 0 1 2 2 6 1
19 2-D 1 0.256 0.256 9,702 8,869 0 2 7 1 2 1
20 O-D 1 0.256 0.256 3,872 3,412 1 3 5 2 2 3
21 3-Q 6 0.148, 0.198, 0.242, 0.276, 0.291, 0.458 0.259 5,580 5,079 2 0 5 4 4 2
22 4-M 1 0.307 0.307 2,953 2,758 1 0 2 3 0 0
23 6-6 1 0.307 0.307 5,364 4,505 3 0 4 1 3 1
24 4-E 2 0.340, 0.360 0.350 3,912 3,586 0 0 0 1 1 0
25 4-L 2 0.310, 0.485 0.398 3,069 2,723 1 1 0 1 1 0
26 4-F 11 0.120, 0.170, 0.229, 0.260, 0.260, 0.406, 0.469, 0.485, 0.595, 0.779, 0.819 0.406 4,482 3,886 2 3 5 1 1 0
27 3-I 1 0.448 0.448 4,551 4,259 2 3 4 3 5 1
28 5-G 1 0.467 0.467 6,179 5,298 7 5 7 1 2 3
29 4-P 1 0.504 0.504 5,843 5,397 1 0 1 1 1 1
30 0-H 5 0.050, 0.394, 0.520, 0.610, 1.752 0.520 4,390 4,313 3 2 4 5 4 0
31 4-I 47 0.020, 0.020, 0.030, 0.090, 0.100, 0.110, 0.120, 0.120, 0.160, 0.190, 0.230, 0.520 4,870 4,432 2 2 3 5 1 0
0.240, 0.250, 0.270, 0.270, 0.290, 0.290, 0.350, 0.370, 0.410, 0.430, 0.450,
0.510, 0.520, 0.540, 0.560, 0.660, 0.700, 0.730, 0.740, 0.760, 0.760, 0.760,
0.780, 0.810, 0.810, 0.840, 0.840, 0.850, 0.850, 0.850, 0.870, 0.890, 0.900,
0.930, 0.940, 0.970
32 3-J 2 0.529, 0.529 0.529 9,454 8,689 4 8 6 5 3 1
33 3-S 2 0.480, 0.595 0.538 4,287 3,667 4 3 8 4 7 0
34 3-9 1 0.544 0.544 3,655 3,413 0 1 1 0 1 1
35 2-2 10 0.560, 0.580, 0.580, 0.590, 0.597, 0.600, 0.618, 0.620, 0.650, 0.704 0.599 9,059 7,977 2 2 8 5 9 5
36 4-G 2 0.620, 0.680 0.650 2,425 2,108 2 0 2 2 0 0
37 5-4 2 0.630, 0.735 0.683 3,155 2,983 1 1 5 2 2 1
38 2-M 2 0.435, 0.950 0.693 11,123 11,263 9 9 14 4 6 4
39 0-F 5 0.415, 0.660, 0.694, 0.720, 0.749 0.694 7,010 5,720 5 1 2 9 8 3
40 3-R 5 0.397, 0.440, 0.698, 0.750, 1.010 0.698 4,310 3,576 3 6 6 7 3 2
41 3-M 4 0.221, 0.329, 1.105, 1.411 0.717 5,815 4,877 0 1 0 4 2 0
42 2-N 3 0.560, 0.934, 0.960 0.934 8,341 8,342 7 10 4 10 8 2
Total 153 256,970 233,959 85 90 144 122 122 51
Abbreviations: F, female; M, male. 
Data from Wu et al. (1989) and Chen et al. (1992). Table from NRC (1999b), reprinted with corrections with permission from the National Academy of Sciences, courtesy of the National
Academies Press. See Supplemental Material for original corrected table with comments (http://www.ehponline.org/members/2006/8704/suppl.pdf)]. For raw data, see the StatLib website
hosted by Carnegie Mellon University (Carnegie Mellon University 2006); click on "Get Data," then search the term “arsenic.”be the actual well of use (Brown and Chen
1995). Well multiplicity was examined as a
surrogate for distinguishing between those
villages that entered the analysis on the basis
of a “median” village well water arsenic level
(i.e., those villages with multiple wells) and
those villages whose exposure assignment was
not based on a median (i.e., single-well vil-
lages). A village was operationally defined as
being "artesian well dependent" if all its wells
had arsenic levels > 0.325 ppm, based on the
observation of Chen et al. (1962) of arsenic
levels in artesian wells in the endemic area,
which was cited by both Chen et al. (1985)
and Wu et al. (1989). The deﬁnition of “low-
dose village exposure” was based on the gap in
the median village well water arsenic levels
between 0.13 and 0.25 ppm and the observa-
tion by Wu et al. (1989) that arsenic content
of well water samples had two clusters, with
the low-dose cluster < 0.25 ppm.
We calculated SMRs for individuals 20 or
more years of age for individual villages or
groups of villages, with SW Taiwan data used
for the reference population. We also calcu-
lated confidence intervals on SMRs from a
Poisson distribution on the basis of the
observed number of cancer deaths. Analysis of
variance (ANOVA), regression analyses, and
hierarchical regression analyses have been per-
formed using SAS software (SAS Institute,
Cary, NC).
Results
The present analysis is based on the
1973–1986 bladder and lung cancer mortality
experience of the 42 villages studied by Wu
et al. (1989)—27 from the study by Chen
et al. (1985) of the four BFD-endemic town-
ships and 15 from two neighboring townships.
In total, this comprises 478,776 person-years
of observation (≥ 20 years of age) and
181 bladder and 268 lung cancer deaths
(449 total deaths). The primary exposure vari-
able is the median village well water arsenic
level that represents one well for 20 villages and
multiple wells (range, 2–47) for the other
22 villages. Overall, linear regression analysis of
the 42-village bladder and lung cancer SMR
data on the median village well artesian level
(parts per million) showed an explanatory
model that accounted for only 21% of the vari-
ability (p = 0.03) (Figure 1). The y-intercept is
at SMR = 189, above the no-increased risk line
at SMR = 100.
A number of investigators have considered
various alternative sources of variability in
order to better understand the data. For exam-
ple, the median village well water level may to
some degree misrepresent the village-specific
exposure because it ignores the marked vari-
ability in well water arsenic measures for a
number of villages. The extreme example is
that of village G in township 0, which has a
range of well water arsenic measurements from
0.010 to 0.770 ppm but enters the analysis
with a median of 0.030 ppm. Chen et al.
(1985), the study that provided data for
two-thirds of these villages (27/42 = 64%),
pointed out that township, BFD prevalence,
and artesian well dependency were each signif-
icant determinants of the cancer risk. Lamm
et al. (2003) demonstrated that artesian well
dependency was at least as strong a determi-
nant of bladder cancer risk in this data set as
was median village well water arsenic level.
We have used the village-speciﬁc data that
are available for the villages studied by Wu
et al. (1989) to examine singly and collectively
the various hypothesized alternative sources of
variability in the regression of cancer mortality
risk (bladder and lung) on arsenic exposure
level (median village well water arsenic level).
Unfortunately, village-speciﬁc BFD prevalence
ratios are not in the available data.
The NRC data (NRC 1999b) allowed us
to examine three dichotomous potential
sources of variability—well multiplicity, arte-
sian well dependency, and exposure strata (low
dose vs. higher dose)—as well as township.
Each of the dichotomous variables was found
to be a predictive factor for bladder and lung
cancers in the one-way ANOVA, with p-values
of 0.01–0.02. 
We have looked at township as a stratifying
variable and examined the dose response
between bladder and lung cancer and median
village well water arsenic level for each of the six
townships. The townships were labeled as 0, 2,
3, 4, 5, and 6, but their speciﬁc identities were
not revealed. Townships 2, 4, and 6 each
showed a statistically significant association
with p-values of 0.019, 0.011, and 0.019,
respectively. Townships 0 and 3 did not show
significant association, with p-values of 0.24
and 0.91, respectively. As township 5 had only
two villages in the study, the p-value is unde-
ﬁned. The townships were grouped into those
that showed a signiﬁcant dose–response rela-
tionship with the arsenic exposure (town-
ships 2, 4, and 6) and those that did not
(townships 0, 3, and 5). Township group (as a
dichotomous variable) was also a significant
determinant of risk (p = 0.006) in a one-way
ANOVA analysis.
Stepwise regression analysis demonstrated
that median village well water arsenic level
(parts per million) and township group were
the only signiﬁcant factors. The inclusion of
either well multiplicity or artesian well depen-
dency did not significantly increase the
explanatory power of the model. The same
result was found for bladder and lung cancer
individually and combined and by sex individ-
ually and combined. The single exception was
that the mortality risk for female lung cancer
was best explained by township group and well
multiplicity but not by median arsenic level.
The combined bladder and lung cancer
mortality was significantly higher in the
higher-dose villages (SMR = 402.5; 95% CI,
358 to 447) than in the low-dose villages
(SMR = 178.5; 95% CI, 148 to 209). The
dose–response relationship was examined
within each subgroup (i.e., the low-dose and
higher-dose villages), with the expectation
that the slope of the dose–response relation-
ship for the higher-exposure villages and the
slope of the dose–response for the low-dose
exposure villages would be similar (Figure 2).
However, the regression lines for the linear
regression analysis of the cancer risk against
median village well water arsenic level (parts
per million) for the low-dose (n = 18) and
higher-dose villages (n = 24) were dissimilar.
The higher-dose villages showed a signiﬁcant
positive dose–response relationship for bladder
Cancer risk in southwest Taiwan: a hypothesis
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Figure 1. Bladder and lung cancer (combined) SMRs for the 42-study villages
by median village well water arsenic level (µg/L). y = 0.429x + 189; R2 = 0.21; 
p = 0.03.
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Figure 2. Bladder and lung cancer (combined) SMRs for low-dose villages and
for higher-dose villages by median village well water arsenic level (µg/L). Low-
dose villages (n = 18): y = 1.275x + 312; R2 = 0.04; p = 0.42. Higher-dose villages
(n = 24): y = 0.639x + 71.2; R2 = 0.24; p = 0.02.
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Higher-doseand lung cancer SMR (n = 24; R2 = 0.24;
p = 0.02), whereas the low-dose villages
showed a nonsignificant negative dose
response for bladder and lung cancer SMR
(n = 18; R2 = 0.04; p = 0.42).
The data for the low-dose villages were
then examined to seek a basis for the negative
slope. Township was examined as a potential
source of cancer risk variability for the low-
dose villages. For instance, the five low-dose
range villages in township 3 had median well
water arsenic levels of 10, 32, 32, 56, and
65 ppb (µg/L), with bladder and lung cancer
SMRs of 649, 348, 568, 587, and 154, respec-
tively, whereas the ﬁve low-dose range villages
in township 4 had median village well water
arsenic levels of 42, 60, 80, 123, and 126 ppb
(µg/L) and bladder and lung cancer SMRs of
0, 81, 75, 96, and 114, respectively. The
18 villages that make up the low-dose group
were from ﬁve townships. There were no vil-
lages from township 5 among the low-dose
villages. Stratiﬁcation of the bladder and lung
cancer SMR analysis by township showed that
the SMRs for townships 2, 4, and 6 were simi-
lar (and < 100) and that the SMRs for town-
ships 0 and 3 were each signiﬁcantly elevated
(Figure 3).
Township-stratified linear regression
analysis for bladder and lung cancer against
median village well water arsenic level (micro-
grams per liter; ppb) for the low-dose villages
yielded positive slopes (dose–response rela-
tionships) for townships 4 and 6 and negative
slopes (dose–response relationships) for town-
ships 0 and 3. Township 2 had only one
village in the low-dose village group, and
township 5 had none.
Thus, among the low-dose villages, town-
ships 0 and 3 each showed a bladder and lung
cancer mortality risk that was significantly
increased over the background, greater than
the risks in townships 2, 4, and 6 and inde-
pendent of the median village well water
arsenic exposure levels. The identity of this
independent township factor is not known,
although it may relate to the BFD prevalence
township factor that Chen et al. (1985) had
previously reported. Nonetheless, these analy-
ses indicate that some geographically related
risk factor exists in townships 0 and 3 that
may be independent of arsenic exposure levels
and appears to confound the dose–response
analysis in the data set. As township 5 had no
village among the low-dose villages and only
two among the higher-dose villages, there
were no data to examine risk at low dose in
township 5.
The data for the 42 villages were separated
into two groups—the data for townships 2, 4,
and 6 that each showed a signiﬁcant relation-
ship to the median village well water arsenic
level (p = 0.01–0.02) and the data for town-
ships 0, 3, and 5 that showed some other pos-
sible nonarsenic carcinogenic risk factor and
no apparent relationship to arsenic level
[p = 0.24, 0.91, and undeﬁned (based on only
two data points), respectively].
Figure 4 shows the dose–response relation-
ship for bladder and lung cancer mortality risk
and median village well water arsenic level by
township group (townships 2, 4, and 6 vs.
townships 0, 3, and 5) for the full set of 42 vil-
lages (range, 0.01–0.934 ppm). Median village
well water arsenic level explains 75% of the
variability in the bladder and lung cancer
SMRs for the 20 villages in township group 2,
4, 6 (p < 0.001) and only 5% of that for the
22 villages in township group 0, 3, 5
(p = 0.30). The regression line for bladder and
lung cancer SMR for township group 2, 4, 6
meets the no-increased-risk line (SMR = 100)
at 151 µg/L with a 95% CI of 42 to 229 µg/L.
The regression line for bladder and lung can-
cer SMR for township group 0, 3, 5 is above
an SMR of 350 at 0 µg/L.
The regression line from bladder and lung
cancer SMR for township group 2, 4, 6,
meets the no-increased-risk line (SMR = 100)
for males at 119 µg/L with a 95% CI of –70
to 229 µg/L and for females at 191 with a
95% CI of 66 to 280 µg/L.
Separate examination of the bladder can-
cer SMRs for the villages in township group 2,
4, 6 showed a signiﬁcant dose–response rela-
tionship with median village well water arsenic
level (p < 0.001) that meets the no-increased-
risk line (SMR = 100) at 139 µg/L with a 95%
CI of –7.5 to 233 µg/L. For the villages in
township group 0, 3, 5, the dose–response
relationship is not signiﬁcant (p = 0.61), and
the regression line is above SMR = 750 at
Lamm et al.
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Figure 3. Bladder and lung cancer (combined) SMR (± 95% CI) for low-dose
villages by township (Twn).
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Figure 4. Bladder and lung cancer (combined) SMRs by township group and
median village well water arsenic level (µg/L). Township group 0, 3, 5 (n = 22): y =
0.200x + 358; R2 = 0.053; p = 0.30. Township group 2, 4, 6 (n = 20): y = 0.704x + 6.26;
R2 = 0.748; p = 0.001.
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Figure 5. Bladder cancer SMRs for township group 2, 4, 6 for male and female
by median village well water arsenic level (µg/L). Male bladder cancer: y =
2.75x + 243; R2 = 0.68; p < 0.001. Female bladder cancer: y = 1.33x + 117; R2 =
0.49; p = 0.001.
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Figure 6. Lung cancer SMRs for township group 2, 4, 6 for male and female by
median village well water arsenic level (µg/L). Male lung cancer: y = 0.536x +
37.5; R2 = 0.40; p = 0.003. Female lung cancer: y = 0.371x + 19.4; R2 = 0.52; 
p < 0.001.0 µg/L (data not shown). Likewise, examina-
tion of the lung cancer SMRs for the villages
in township group 2, 4, 6 showed a signiﬁcant
dose–response relationship with median vil-
lage well water arsenic level (p < 0.001) that
meets the no-increased-risk line (SMR = 100)
at 164 µg/L with a 95% CI of 26 to 257 µg/L.
For the villages in township group 0, 3, 5,
dose–response relationship is not significant
(p = 0.16) and the regression line is above
SMR = 250 at 0 µg/L (data not shown).
Further analysis was conducted among
those townships (townships 2, 4, and 6) that
appeared to show some relationship between
cancer risk and arsenic exposure, eliminating
those townships that appeared to have some
other strong risk factor for bladder and lung
cancer that was not related to the arsenic
exposure (townships 0, 3, and 5).
Figure 5 demonstrates, for male bladder
cancer mortality in township group 2, 4, 6, a
regression line (p < 0.001) that meets the no-
increased-risk line (SMR = 100) at 125 µg/L
with a 95% CI of –19 to 218 µg/L, and for
female bladder cancer mortality, a regression
line (p = 0.001) that meets the no-increased-
risk line (SMR = 100) at 163 µg/L with a
95% CI of –80 to 294 µg/L.
Figure 6 demonstrates for male lung can-
cer mortality in township group 2, 4, 6, a
regression line (p < 0.001) that meets the no-
increased-risk line (SMR = 100) at 117 µg/L
with a 95% CI of –274 to 273 µg/L, and for
female lung cancer mortality, a regression line
(p = 0.001) that meets the no-increased-risk
line (SMR = 100) at 217 µg/L with 95% CI
of 31 to 273 µg/L.
Figure 7 summarizes for township
group 2, 4, 6 the exposure levels at which the
regression line meets the no-increased-risk
line (SMR = 100) with the 95% CI of that
intercept in micrograms per liter arsenic.
Most of these levels are in the range of
100–200 µg/L and statistically significantly
different from zero overall. The fact that the
intercept levels for females are greater than
those for males and tend to be statistically sig-
niﬁcantly different from zero while those for
the males do not, may reflect the effects of
cigarette smoking, which is far less prevalent
among the females than among the males.
Discussion
Analysis of the bladder and lung cancer mor-
tality data from the 42 study villages of the
BFD-endemic area of SW Taiwan from the
Wu et al. (1989) study showed only a 21%
explanatory power when median village well
water arsenic level is used as the sole explana-
tory variable in the linear regression model
(p = 0.03). Separation of low-dose villages
from higher-dose villages showed that the
explanatory power resided among the higher-
dose villages and did not appear among the
low-dose villages. Previous analysis of the can-
cer mortality in the BFD-endemic had shown
that township was a discriminating variable for
the cancer mortality risk in this area (Chen
et al. 1985). The mortality experience for the
low-dose villages was examined to explore the
contribution potentially made by township.
Within that analysis, certain townships
(townships 0 and 3) were found each to have
an increased cancer risk that was not related
to arsenic exposure level, and other townships
(townships 2, 4, and 6) were found to have
cancer risks similar to each other with SMRs
less than 100. The full 42-village data set was
stratified by township group in order to
examine the dose–response relationship in the
absence of the interfering township factor. A
significant positive dose response was seen
with the data from townships 2, 4, and 6,
with the explanatory power raised to 75%
(p < 0.001). No significant positive dose
response was seen with the data from town-
ships 0, 3, and 5 (p = 0.30). Removal of the
data from the townships influenced by the
township factor markedly improved the ﬁt of
the data and the explanatory power of the
model. If the SW Taiwan data are going to be
used in formal risk analysis for ingested
arsenic, the analysis should be restricted to the
data from townships 2, 4, and 6.
The identity of this independent township
factor is not known and may relate to the BFD
prevalence township factor that Chen et al.
(1985) had previously demonstrated. The data
from Chen and Wu (1962) showed among the
townships that the average number of wells per
village, the proportion of villages with artesian
well dependency, and the BFD prevalence
were signiﬁcantly correlated. Without knowing
the speciﬁc identity and location of each study
village, these various factors cannot be disen-
tangled. Figure 8 shows that the BFD case dis-
tribution (Ch’i and Blackwell 1968) was not
uniform over the study area. The number of
BFD cases seems to be heavily concentrated in
the three townships to the left of the ﬁgure.
The township factor may be a reﬂection of
a selection bias occurring because the well
water sampling was focused on the villages
with high prevalence of BFD. Because the vil-
lages in the Wu et al. (1989) study were
speciﬁcally selected because well water arsenic
data from the 1960s existed for them, such a
selection bias may have entered that could
skew the interpretation of the results. High
BFD prevalence was found in most but not all
of the townships of Pei-men, Hsieh-chia, and
Pu-tai; moderate prevalence, in the southern
part of I-chu; and near absence in Hsia-in and
Yen-shui. Again, it may not be possible to dis-
entangle the relationship between BFD and
any other possible etiologic factor for any out-
come of interest, at least until each village can
be speciﬁcally located on this map.
The “true” underlying structure of the
arsenic dose–response relationship is more
likely to be seen in the analysis of the cancer
risks in townships 2, 4, and 6 than in that of
the entire data set that contains the inﬂuence of
the township factor. Removal of this extraneous
source of variability has allowed for a clearer
examination of the dose–response relationship.
Interestingly, analysis of the bladder cancer
mortality data for townships 2, 4, and 6 appears
Cancer risk in southwest Taiwan: a hypothesis
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Figure 7. Exposure level (µg/L arsenic) at no-increased-risk level (SMR = 100) by cancer group for town-
ship group 2, 4, 6 (± 95% CI).
Figure 8. Distribution of BFD cases in the 1960s by
township [adapted from Ch’i and Blackwell (1968)
with permission of Oxford University Press].to display a ﬁt to a threshold model. This ﬁnd-
ing for bladder cancer mortality is indepen-
dently seen in males and females, suggesting
that it may reﬂect a real phenomenon.
A thresholdlike model indicating that the
bladder cancer mortality risk does not increase
with exposure levels < 150 µg/L is consistent
with other epidemiologic data. An ecologic
analysis of the white male bladder cancer risk
in the United States found no increase over an
arsenic exposure range of 3–59 µg/L (Lamm
et al. 2004). Case–control bladder cancer
studies found no increased risk in the United
States for exposures < 80 µg/day (Steinmaus
et al. 2003) or < 160 µg/L (Bates et al. 1995)
or in Argentina with exposures > 200 µg/L
(Bates et al. 2004). The prospective cohort
study in northeastern Taiwan reported that
the multivariate-adjusted relative risk of uri-
nary tract cancer was statistically signiﬁcant for
residents who drank well water containing
arsenic at levels > 100 µg/L (Chiou et al.
2001). Cigarette smoking still remains a risk
factor for bladder cancer.
A threshold, sublinear, or hormetic model
for bladder cancer and inorganic arsenic expo-
sure has been proposed from toxicologic stud-
ies, based on a number of modes of action
(Snow et al. 2005). All three model forms
have in common an inﬂection point wherein
the risks at exposure levels greater than the
inflection point do not predict the risks for
exposures less than the inﬂection point expo-
sure level. Suggested modes of action include
generation of oxidative stress, perturbation of
DNA methylation patterns, inhibition of
DNA repair, and modulation of signal trans-
duction pathways (Schoen et al. 2004).
Cellular proliferation has been recognized as
an early step in the development of bladder
cancer by substances that are not mutagenic,
such as inorganic arsenic (Cohen 2002).
A similar inflection point is seen in the
analysis of the lung cancer mortality data and
is statistically signiﬁcant in females but not in
males, although that question may not be
answerable in the absence of smoking history.
Perhaps analysis of lung cancer mortality in
the northeastern Taiwan prospective study
where smoking histories have been obtained
would allow for a better assessment.
Conclusion
Exploration of the SW Taiwan cancer mortal-
ity data set from the BFD-endemic area has
identified significant confounding variables.
Certain townships in the study demonstrate a
signiﬁcantly increased cancer risk at low-dose
exposures that is independent of the village
arsenic exposure levels. Removal of the data
confounded by the township factor reveals an
underlying dose–response curve for bladder
and lung cancer mortality and arsenic level
(median village well water arsenic level) that
displays as a thresholdlike model. Such a
model would not be contradicted by either
the epidemiologic or the toxicologic litera-
ture, at least for bladder cancer.
The variability in the village SMRs, partic-
ularly the low-dose high-rate villages, is not
explained by any biological model that uses
arsenic as the sole explanatory variable. It is
reasonable to assume that they are high for
some nonarsenic reason. As Chen et al. (1985)
demonstrated, the cancer mortality in the
study area showed a dose–response relationship
with BFD prevalence at both a village and
township level of analysis. We have followed
through from these ﬁndings and have analyzed
separately the data from the townships that do
not appear to have been strongly inﬂuenced by
this second factor that may be related to BFD
prevalence. It is likely that the cancer dose–
response relationship is more clearly seen in
those areas that have little or no confounding
by BFD prevalence.
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CORRECTION
The following figures have been modified
from the originally published article online:
Figure 1: Now includes the horizontal
regression line at SMR = 100 to indicate the
level at which no increased risk is observed.
Figure 3: Now includes township group 0,
3, 5 (Twn grp 0, 3, 5). A vertical line has been
added to separate the township-speciﬁc results
within each township, and the 95% CI values
have been added to the Twn 2 data point. 
Figure 7: 95% CI values have been cor-
rected for female bladder and female lung
cancers. 
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